Cargando…
Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H
Botulinum neurotoxins (BoNTs), which have been exploited as cosmetics and muscle-disorder treatment medicines for decades, are well known for their extreme neurotoxicity to humans. They pose a potential bioterrorism threat because they cause botulism, a flaccid muscular paralysis-associated disease...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371848/ https://www.ncbi.nlm.nih.gov/pubmed/28282873 http://dx.doi.org/10.3390/toxins9030093 |
_version_ | 1782518504776269824 |
---|---|
author | Yao, Guorui Lam, Kwok-ho Perry, Kay Weisemann, Jasmin Rummel, Andreas Jin, Rongsheng |
author_facet | Yao, Guorui Lam, Kwok-ho Perry, Kay Weisemann, Jasmin Rummel, Andreas Jin, Rongsheng |
author_sort | Yao, Guorui |
collection | PubMed |
description | Botulinum neurotoxins (BoNTs), which have been exploited as cosmetics and muscle-disorder treatment medicines for decades, are well known for their extreme neurotoxicity to humans. They pose a potential bioterrorism threat because they cause botulism, a flaccid muscular paralysis-associated disease that requires immediate antitoxin treatment and intensive care over a long period of time. In addition to the existing seven established BoNT serotypes (BoNT/A–G), a new mosaic toxin type termed BoNT/HA (aka type FA or H) was reported recently. Sequence analyses indicate that the receptor-binding domain (H(C)) of BoNT/HA is ~84% identical to that of BoNT/A1. However, BoNT/HA responds differently to some potent BoNT/A-neutralizing antibodies (e.g., CR2) that target the H(C). Therefore, it raises a serious concern as to whether BoNT/HA poses a new threat to our biosecurity. In this study, we report the first high-resolution crystal structure of BoNT/HA-H(C) at 1.8 Å. Sequence and structure analyses reveal that BoNT/HA and BoNT/A1 are different regarding their binding to cell-surface receptors including both polysialoganglioside (PSG) and synaptic vesicle glycoprotein 2 (SV2). Furthermore, the new structure also provides explanations for the ~540-fold decreased affinity of antibody CR2 towards BoNT/HA compared to BoNT/A1. Taken together, these new findings advance our understanding of the structure and function of this newly identified toxin at the molecular level, and pave the way for the future development of more effective countermeasures. |
format | Online Article Text |
id | pubmed-5371848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-53718482017-04-10 Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H Yao, Guorui Lam, Kwok-ho Perry, Kay Weisemann, Jasmin Rummel, Andreas Jin, Rongsheng Toxins (Basel) Article Botulinum neurotoxins (BoNTs), which have been exploited as cosmetics and muscle-disorder treatment medicines for decades, are well known for their extreme neurotoxicity to humans. They pose a potential bioterrorism threat because they cause botulism, a flaccid muscular paralysis-associated disease that requires immediate antitoxin treatment and intensive care over a long period of time. In addition to the existing seven established BoNT serotypes (BoNT/A–G), a new mosaic toxin type termed BoNT/HA (aka type FA or H) was reported recently. Sequence analyses indicate that the receptor-binding domain (H(C)) of BoNT/HA is ~84% identical to that of BoNT/A1. However, BoNT/HA responds differently to some potent BoNT/A-neutralizing antibodies (e.g., CR2) that target the H(C). Therefore, it raises a serious concern as to whether BoNT/HA poses a new threat to our biosecurity. In this study, we report the first high-resolution crystal structure of BoNT/HA-H(C) at 1.8 Å. Sequence and structure analyses reveal that BoNT/HA and BoNT/A1 are different regarding their binding to cell-surface receptors including both polysialoganglioside (PSG) and synaptic vesicle glycoprotein 2 (SV2). Furthermore, the new structure also provides explanations for the ~540-fold decreased affinity of antibody CR2 towards BoNT/HA compared to BoNT/A1. Taken together, these new findings advance our understanding of the structure and function of this newly identified toxin at the molecular level, and pave the way for the future development of more effective countermeasures. MDPI 2017-03-08 /pmc/articles/PMC5371848/ /pubmed/28282873 http://dx.doi.org/10.3390/toxins9030093 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yao, Guorui Lam, Kwok-ho Perry, Kay Weisemann, Jasmin Rummel, Andreas Jin, Rongsheng Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H |
title | Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H |
title_full | Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H |
title_fullStr | Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H |
title_full_unstemmed | Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H |
title_short | Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H |
title_sort | crystal structure of the receptor-binding domain of botulinum neurotoxin type ha, also known as type fa or h |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371848/ https://www.ncbi.nlm.nih.gov/pubmed/28282873 http://dx.doi.org/10.3390/toxins9030093 |
work_keys_str_mv | AT yaoguorui crystalstructureofthereceptorbindingdomainofbotulinumneurotoxintypehaalsoknownastypefaorh AT lamkwokho crystalstructureofthereceptorbindingdomainofbotulinumneurotoxintypehaalsoknownastypefaorh AT perrykay crystalstructureofthereceptorbindingdomainofbotulinumneurotoxintypehaalsoknownastypefaorh AT weisemannjasmin crystalstructureofthereceptorbindingdomainofbotulinumneurotoxintypehaalsoknownastypefaorh AT rummelandreas crystalstructureofthereceptorbindingdomainofbotulinumneurotoxintypehaalsoknownastypefaorh AT jinrongsheng crystalstructureofthereceptorbindingdomainofbotulinumneurotoxintypehaalsoknownastypefaorh |